MEI Pharma, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc 23.92%76.576.5%$149.74m
VRXValeant Pharmaceuticals International, Inc. 1.90%19.3514.1%$113.86m
CTLTCatalent, Inc. 1.60%89.592.1%$94.48m
JAZZJazz Pharmaceuticals Plc 10.79%122.402.4%$64.86m
BHCBausch Health Cos., Inc. 1.92%19.360.0%$64.82m
TNXPTonix Pharmaceuticals Holding Corp. 4.13%1.263.9%$62.68m
ARGXargenx SE -0.05%231.500.0%$46.59m
PCRXPacira Biosciences, Inc. 1.56%56.1410.3%$44.58m
ICLRICON plc 1.41%189.734.3%$42.42m
UTHRUnited Therapeutics Corp. -0.78%113.2014.1%$42.15m
ICPTIntercept Pharmaceuticals, Inc. 0.62%47.8816.8%$41.72m
PRGOPerrigo Co. Plc -5.26%52.226.8%$40.07m
GWPHGW Pharmaceuticals Plc -0.44%134.786.2%$38.00m
MYOKMyoKardia, Inc. 2.04%100.001.8%$36.78m
AMRNAmarin Corp. Plc -2.92%6.831.5%$36.26m

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.